| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 51991-0797-98 | 51991-0797 | Azacitidine | Azacitidine | 100.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Subcutaneous | Aug 7, 2017 | Jan 31, 2024 | No Longer Used |
| 50242-0933-86 | 50242-0933 | Atezolizumab and hyaluronidase-tqjs | Tecentriq Hybreza | 1875.0 mg/15mL, 30000.0 U/15mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Subcutaneous | Sep 12, 2024 | In Use | |
| 00004-0357-30 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Mar 29, 2011 | Jun 30, 2024 | No Longer Used |
| 00143-9166-01 | 00143-9166 | Denosumab-qbde | XTRENBO | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jan 8, 2026 | In Use | |
| 55513-0730-01 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Nov 18, 2010 | In Use | |
| 71202-0012-11 | 71202-0012 | Denosumab | OSPOMYV | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 1, 2025 | Oct 31, 2025 | In Use |
| 85043-0045-04 | 85043-0045 | Leuprolide acetate | Vabrinty | 45.0 mg/.375mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug 4, 2025 | In Use | ||
| 43598-0308-23 | 43598-0308 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Nov 6, 2023 | In Use | |
| 70710-1769-03 | 70710-1769 | LEUPROLIDE ACETATE | LEUPROLIDE ACETATE | 1.0 mg/0.2ml | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 8, 2026 | In Use | ||
| 63459-0910-15 | 63459-0910 | tbo-filgrastim | Granix | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
| 72843-0591-99 | 72843-0591 | Leuprolide acetate | Leuprolide acetate | 5.0 mg/ml | Hormonal Therapy | GnRH Agonist | Subcutaneous | Oct 25, 2024 | In Use | ||
| 72603-0402-01 | 72603-0402 | Pegflilgrastim-fpgk | STIMUFEND | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Subcutaneous | Dec 29, 2025 | In Use | |
| 76282-0720-67 | 76282-0720 | LANREOTIDE ACETATE | LANREOTIDE ACETATE | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | May 30, 2025 | In Use | ||
| 72606-0037-01 | 72606-0037 | Denosumab-bmwo | Stoboclo | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 2, 2025 | In Use | |
| 83257-0029-41 | 83257-0029 | Denosumab-kyqq | BOSAYA | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jan 5, 2026 | In Use | |
| 71202-0012-10 | 71202-0012 | Denosumab | OSPOMYV | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 1, 2025 | Oct 31, 2025 | In Use |
| 78206-0193-01 | 78206-0193 | Denosumab | BILDYOS | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Sep 11, 2025 | In Use | |
| 15054-0090-01 | 15054-0090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov 14, 2007 | Aug 31, 2016 | No Longer Used | |
| 00006-3083-01 | 00006-3083 | Pembrolizumab and berahyaluronidase alfa-pmph | KEYTRUDA QLEX | 2000.0 U/mL, 165.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Subcutaneous | Sep 19, 2025 | In Use | |
| 59572-0775-01 | 59572-0775 | Luspatercept | Reblozyl | 75.0 mg/1 | Immunotherapy | Erythropoiesis-Stimulating Agent | Subcutaneous | Nov 8, 2019 | In Use | ||
| 63459-0912-11 | 63459-0912 | tbo-filgrastim | Granix | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
| 75987-0111-11 | 75987-0111 | Interferon gamma-1b | Actimmune | 100.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Dec 1, 2013 | In Use | |
| 61314-0866-02 | 61314-0866 | Pegfilgrastim-bmez | ZIEXTENZO | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | Subcutaneous | Mar 3, 2025 | In Use | |
| 62935-0303-30 | 62935-0303 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Feb 26, 2003 | In Use | |||
| 50242-0245-86 | 50242-0245 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use |
Found 12250 results — Export these results
Home